tiprankstipranks
Advertisement
Advertisement

UPB Stock Latest News

Upstream Bio initiated with a Buy at H.C. Wainwright
The FlyUpstream Bio initiated with a Buy at H.C. Wainwright
1d ago
UPB
Upstream Bio Maintained at Buy as Verekitug’s Differentiated Efficacy Supports Steady $42 Price Target
PremiumRatings
Upstream Bio Maintained at Buy as Verekitug’s Differentiated Efficacy Supports Steady $42 Price Target
16d ago
UPB
Upstream Bio presents data from Phase 2 VIBRANT trial of verekitug
PremiumThe Fly
Upstream Bio presents data from Phase 2 VIBRANT trial of verekitug
17d ago
UPB
Upstream Bio price target lowered to $50 from $51 at Mizuho
PremiumThe Fly
Upstream Bio price target lowered to $50 from $51 at Mizuho
21d ago
UPB
Yaron Werber Reiterates Buy Rating on Verekitug Developer, Citing Differentiated TSLP Profile, Streamlined Late‑Stage Path, and Cash Runway Through 2027
PremiumRatings
Yaron Werber Reiterates Buy Rating on Verekitug Developer, Citing Differentiated TSLP Profile, Streamlined Late‑Stage Path, and Cash Runway Through 2027
22d ago
UPB
Upstream Bio reports Q1 revenue $1.03M, consensus $347,170
PremiumThe FlyUpstream Bio reports Q1 revenue $1.03M, consensus $347,170
22d ago
UPB
Upstream Bio to present new data from Phase 2 Vibrant trial of Verekitug
Premium
The Fly
Upstream Bio to present new data from Phase 2 Vibrant trial of Verekitug
2M ago
UPB
3 Best High-Risk, High-Reward Stocks to Buy Now, According to Analysts – 4/9/2026
Premium
Market News
3 Best High-Risk, High-Reward Stocks to Buy Now, According to Analysts – 4/9/2026
2M ago
UPB
AIOT
Validating the IL-13/TSLP Axis: Upstream Bio’s Verekitug Positioned for Differentiated Asthma Efficacy and Favorable Risk–Reward
PremiumRatings
Validating the IL-13/TSLP Axis: Upstream Bio’s Verekitug Positioned for Differentiated Asthma Efficacy and Favorable Risk–Reward
2M ago
UPB
VALIANT Asthma Trial Update: What Upstream Bio’s Phase 2 Milestone Means for Investors
PremiumCompany Announcements
VALIANT Asthma Trial Update: What Upstream Bio’s Phase 2 Milestone Means for Investors
2M ago
UPB
Midday Fly By: Carnival cuts forecast on fuel cost, Novartis to buy Excellergy
PremiumThe Fly
Midday Fly By: Carnival cuts forecast on fuel cost, Novartis to buy Excellergy
2M ago
U
CG
Wix downgraded, TripAdvisor upgraded: Wall Street’s top analyst calls
PremiumThe Fly
Wix downgraded, TripAdvisor upgraded: Wall Street’s top analyst calls
2M ago
TW
AGX
Upstream Bio downgraded to In Line from Outperform at Evercore ISI
PremiumThe FlyUpstream Bio downgraded to In Line from Outperform at Evercore ISI
2M ago
UPB
Upstream Bio Launches $150 Million At-The-Market Program
Premium
Company Announcements
Upstream Bio Launches $150 Million At-The-Market Program
2M ago
8K
UPB
Upstream Bio Initiated at Buy: Verekitug’s Quarterly Dosing Strategy Positions It for Potential Best-in-Class Efficacy vs. TSLP Competitors
Premium
Ratings
Upstream Bio Initiated at Buy: Verekitug’s Quarterly Dosing Strategy Positions It for Potential Best-in-Class Efficacy vs. TSLP Competitors
2M ago
UPB
Verekitug’s Differentiated Long-Interval Dosing and Late-Stage Pipeline Position It as a Potential Respiratory Blockbuster
PremiumRatings
Verekitug’s Differentiated Long-Interval Dosing and Late-Stage Pipeline Position It as a Potential Respiratory Blockbuster
2M ago
UPB
Buy Rating Backed by VALIANT Phase 2 Asthma Data and Differentiated, Infrequent-Dosing Profile for Verekitug
PremiumRatings
Buy Rating Backed by VALIANT Phase 2 Asthma Data and Differentiated, Infrequent-Dosing Profile for Verekitug
2M ago
UPB
Is UPB a Buy, Before Earnings?
PremiumPre-Earnings
Is UPB a Buy, Before Earnings?
3M ago
UPB
Buy Rating on UPB Driven by Robust Verekitug Phase 2 Data and Upcoming Phase 3 Catalysts in CRSwNP and Severe Asthma
PremiumRatings
Buy Rating on UPB Driven by Robust Verekitug Phase 2 Data and Upcoming Phase 3 Catalysts in CRSwNP and Severe Asthma
3M ago
UPB
3 Best Stocks With 125%+ Upside Ahead, According to Top Analysts, 3/2/2026
PremiumMarket News3 Best Stocks With 125%+ Upside Ahead, According to Top Analysts, 3/2/2026
3M ago
UPB
VERA
Upstream Bio announces verekitug met the primary endpoint
Premium
The Fly
Upstream Bio announces verekitug met the primary endpoint
3M ago
UPB
XBI vs. IBB: Which Biotech ETF do Analysts Prefer in 2026?
Premium
Market News
XBI vs. IBB: Which Biotech ETF do Analysts Prefer in 2026?
4M ago
IBB
UPB

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >